Liu Wei, Li Yi, Li Rui, Han Xiao, Ma Ying, Liu Bin, Kong Xiangzhen
The School of Nuclear Science and Technology Lanzhou University, School/Hospital of Stomatology Lanzhou University, Lanzhou City 730000, Gansu Province, China.
The co-first author, School of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, Gansu Province, China.
Afr J Tradit Complement Altern Med. 2016 Aug 12;13(5):72-86. doi: 10.21010/ajtcam.v13i5.11. eCollection 2016.
Recent years have witnessed the discovery of similar gene variations between breast cancer and ovarian cancer, inherited breast and ovarian cancer in particular. A large number of case-control studies have been conducted to explore the association of Methylenetetrahydrofolate Reductase (MTHFR) A1298C polymorphism with breast cancer and/or ovarian cancer risk. However, the results are still inconsistent and inconclusive. Consequently, we performed a meta-analysis to evaluate the association between MTHFR A1298C polymorphism and breast, ovarian cancer risk.
A comprehensive retrieval was conducted in the electronic database of PubMed, Web of Science and Chinese National Knowledge Infrastructure (CNKI) until June 2015 to identify eligible studies. A total of 35 studies which examined the association of MTHFR A1298C polymorphism with breast cancer and/or ovarian cancer were identified. The pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the effect of gene polymorphism. And allele model, homozygous model, co-dominant model, dominant model, recessive model were applied.
In the overall analysis, significantly increased breast cancer and/or ovarian cancer risk was found (for allele model A VS C OR = 1.05, CI: 1.02-1.08, P = 4χ10; for homozygous model AA VS CC OR = 1.11, CI: 1.03-1.19, P = 5χ10; for recessive model (AC +AA) VS CC: OR = 1.10, CI: 1.03-1.18, P = 7χ10).
In the subgroup analysis, significantly increased breast cancer risk was identified among Caucasians. MTHFR A1298C polymorphism might contribute to an increased risk of breast cancer and/or ovarian cancer susceptibility. In addition, MTHFR A1298C polymorphism had a significant association with breast cancer in Caucasians.
近年来，人们发现乳腺癌和卵巢癌之间存在相似的基因变异，尤其是遗传性乳腺癌和卵巢癌。大量病例对照研究已开展，以探讨亚甲基四氢叶酸还原酶（MTHFR）A1298C多态性与乳腺癌和/或卵巢癌风险的关联。然而，结果仍不一致且尚无定论。因此，我们进行了一项荟萃分析，以评估MTHFR A1298C多态性与乳腺癌、卵巢癌风险之间的关联。
截至2015年6月，在PubMed、科学网和中国知网电子数据库中进行全面检索，以确定符合条件的研究。共识别出35项研究，这些研究检测了MTHFR A1298C多态性与乳腺癌和/或卵巢癌的关联。采用合并比值比（OR）及95%置信区间（CI）来评估基因多态性的效应。并应用等位基因模型、纯合子模型、共显性模型、显性模型、隐性模型。
在总体分析中，发现乳腺癌和/或卵巢癌风险显著增加（等位基因模型A与C相比，OR = 1.05，CI：1.02 - 1.08），P = 4×10；纯合子模型AA与CC相比，OR = 1.11，CI：1.03 - 1.19，P = 5×10；隐性模型（AC + AA）与CC相比：OR = 1.10，CI：1.03 - 1.18，P = 7×10）。
在亚组分析中，白种人中乳腺癌风险显著增加。MTHFR A1298C多态性可能导致乳腺癌和/或卵巢癌易感性风险增加。此外，MTHFR A1298C多态性与白种人中的乳腺癌存在显著关联。
